...
sgmo-img

Sangamo Therapeutics Inc, Common Stock

SGMO

NAQ

$2.39

-$0.08

(-3.24%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$563.24M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.85M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.10
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.3 L
$3.18 H
$2.39

About Sangamo Therapeutics Inc, Common Stock

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSGMOSectorS&P500
1-Week Return-9.64%-0.94%-2.6%
1-Month Return23.2%-5.08%-1.08%
3-Month Return161.2%-10.62%3.45%
6-Month Return408.73%-6.18%8.57%
1-Year Return402.52%1.98%24.3%
3-Year Return-72.14%-0.93%25.58%
5-Year Return-73.3%33.84%84.07%
10-Year Return-83%102.52%185.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue102.43M118.19M110.70M111.30M176.23M[{"date":"2019-12-31","value":58.12,"profit":true},{"date":"2020-12-31","value":67.07,"profit":true},{"date":"2021-12-31","value":62.82,"profit":true},{"date":"2022-12-31","value":63.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue145.92M180.65M9.44M12.11M221.56M[{"date":"2019-12-31","value":65.86,"profit":true},{"date":"2020-12-31","value":81.54,"profit":true},{"date":"2021-12-31","value":4.26,"profit":true},{"date":"2022-12-31","value":5.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit102.43M118.19M110.70M111.30M(45.33M)[{"date":"2019-12-31","value":86.66,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":93.66,"profit":true},{"date":"2022-12-31","value":94.17,"profit":true},{"date":"2023-12-31","value":-38.35,"profit":false}]
Gross Margin100.00%100.00%100.00%100.00%(25.72%)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-25.72,"profit":false}]
Operating Expenses207.61M247.74M294.04M312.58M450.24M[{"date":"2019-12-31","value":46.11,"profit":true},{"date":"2020-12-31","value":55.03,"profit":true},{"date":"2021-12-31","value":65.31,"profit":true},{"date":"2022-12-31","value":69.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(105.18M)(129.55M)(183.34M)(201.28M)(274.00M)[{"date":"2019-12-31","value":-10518000000,"profit":false},{"date":"2020-12-31","value":-12955200000,"profit":false},{"date":"2021-12-31","value":-18333700000,"profit":false},{"date":"2022-12-31","value":-20128100000,"profit":false},{"date":"2023-12-31","value":-27400500000,"profit":false}]
Total Non-Operating Income/Expense19.52M17.55M10.69M18.86M24.39M[{"date":"2019-12-31","value":80.04,"profit":true},{"date":"2020-12-31","value":71.96,"profit":true},{"date":"2021-12-31","value":43.84,"profit":true},{"date":"2022-12-31","value":77.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(95.42M)(120.78M)(177.99M)(191.85M)(262.90M)[{"date":"2019-12-31","value":-9541900000,"profit":false},{"date":"2020-12-31","value":-12077700000,"profit":false},{"date":"2021-12-31","value":-17799100000,"profit":false},{"date":"2022-12-31","value":-19184900000,"profit":false},{"date":"2023-12-31","value":-26290300000,"profit":false}]
Income Taxes(19.60M)345.00K306.00K429.00K(5.07M)[{"date":"2019-12-31","value":-4569,"profit":false},{"date":"2020-12-31","value":80.42,"profit":true},{"date":"2021-12-31","value":71.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1182.28,"profit":false}]
Income After Taxes(75.82M)(121.12M)(178.30M)(192.28M)(257.83M)[{"date":"2019-12-31","value":-7581800000,"profit":false},{"date":"2020-12-31","value":-12112200000,"profit":false},{"date":"2021-12-31","value":-17829700000,"profit":false},{"date":"2022-12-31","value":-19227800000,"profit":false},{"date":"2023-12-31","value":-25783100000,"profit":false}]
Income From Continuous Operations(95.42M)(121.12M)(178.30M)(192.28M)(249.51M)[{"date":"2019-12-31","value":-9541900000,"profit":false},{"date":"2020-12-31","value":-12112200000,"profit":false},{"date":"2021-12-31","value":-17829700000,"profit":false},{"date":"2022-12-31","value":-19227800000,"profit":false},{"date":"2023-12-31","value":-24950900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(75.82M)(121.12M)(178.30M)(192.28M)(257.83M)[{"date":"2019-12-31","value":-7581800000,"profit":false},{"date":"2020-12-31","value":-12112200000,"profit":false},{"date":"2021-12-31","value":-17829700000,"profit":false},{"date":"2022-12-31","value":-19227800000,"profit":false},{"date":"2023-12-31","value":-25783100000,"profit":false}]
EPS (Diluted)(0.84)(0.93)(1.24)(1.25)(1.47)[{"date":"2019-12-31","value":-84,"profit":false},{"date":"2020-12-31","value":-93,"profit":false},{"date":"2021-12-31","value":-124,"profit":false},{"date":"2022-12-31","value":-125,"profit":false},{"date":"2023-12-31","value":-147,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SGMO
Cash Ratio 0.91
Current Ratio 1.35

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SGMO
ROA (LTM) -58.29%
ROE (LTM) -194.05%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SGMO
Debt Ratio Lower is generally better. Negative is bad. 0.65
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.35

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SGMO
Trailing PE NM
Forward PE NM
P/S (TTM) 9.86
P/B 12.32
Price/FCF 48
EV/R 9.00
EV/Ebitda NM
PEG NM

FAQs

What is Sangamo Therapeutics Inc share price today?

Sangamo Therapeutics Inc (SGMO) share price today is $2.39

Can Indians buy Sangamo Therapeutics Inc shares?

Yes, Indians can buy shares of Sangamo Therapeutics Inc (SGMO) on Vested. To buy Sangamo Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SGMO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Sangamo Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Sangamo Therapeutics Inc (SGMO) via the Vested app. You can start investing in Sangamo Therapeutics Inc (SGMO) with a minimum investment of $1.

How to invest in Sangamo Therapeutics Inc shares from India?

You can invest in shares of Sangamo Therapeutics Inc (SGMO) via Vested in three simple steps:

  • Click on Sign Up or Invest in SGMO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Sangamo Therapeutics Inc shares
What is Sangamo Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Sangamo Therapeutics Inc (SGMO) is $3.18. The 52-week low price of Sangamo Therapeutics Inc (SGMO) is $0.3.

What is Sangamo Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Sangamo Therapeutics Inc (SGMO) is

What is Sangamo Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Sangamo Therapeutics Inc (SGMO) is 12.32

What is Sangamo Therapeutics Inc dividend yield?

The dividend yield of Sangamo Therapeutics Inc (SGMO) is 0.00%

What is the Market Cap of Sangamo Therapeutics Inc?

The market capitalization of Sangamo Therapeutics Inc (SGMO) is $563.24M

What is Sangamo Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Sangamo Therapeutics Inc is SGMO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top